Histone methyltransferase KMT5C drives liver cancer progression and directs therapeutic response to PARP inhibitors.

Yu Tong,Fan Wang,Songling Li,Wenyun Guo,Qianyu Li, Yifei Qian,Linfeng Li,Huifang Zhao,Yonglong Zhang,Wei-Qiang Gao,Yanfeng Liu

Hepatology (Baltimore, Md.)（2023）

引用 0|浏览10

暂无评分

摘要

KMT5C played a vital role in promoting liver cancer progression by activating the DNA repair response. Our results revealed a novel therapeutic approach using the KMT5C inhibitor A196, concurrent with olaparib, as a potential HCC therapy.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要